Caution Signs Are Flashing in My Mind as the New Year Begins
The biotech sector looks ripe for staging a comeback, but a significant geopolitical event could throw the entire market for a loop.
I Don't Love Biogen, But Here's How to Trade It
I'm not saying get married to the stock, I'm saying that the idea could be a trade based on two possible catalysts.
These 2 Undervalued Biotechs Are Ripe for Acquisition
Mirum Pharmaceuticals and TG Therapeutics are undervalued as stand-alone entities, but also would make easy and logical targets for a larger player.
Why AT&T 'Fits the Mold' for Investors in 2022
The beaten-down name is finally lining up as an attractive value play.
Here's Where Oracle Is Worth a Shot
In a market filled with charts without a clear stop, ORCL offers that.
Cerner Finally Reaches Our Price Target From Long Ago
Oracle's acquisition bid today for CERN of about $28.3B certainly helped us get there.
The Bedraggled Biotech Sector Finally Offers a Glimmer of Hope
Two recent acquisition deals and big drug companies that are flush with cash provide reason to believe biotech stocks could rebound in 2022
Everyone Is Watching Inflation, but I've Got My Eyes on M&A
Here's why I say, don't worry about the Fed, D.C. or inflation, and instead look at this big deal.
What Do We See Next for Soaring Unity Software?
It may be time to take some money off the table.
DoorDash Delivers a Surprise That Its Charts Didn't Detect
The shares of the food delivery service are climbing after word of a deal to acquire rival Wolt Enterprises, which will expand its presence in Europe.